

Title (en)

PRODRUGS OF THE TYROSINE KINASE INHIBITOR FOR TREATING CANCER

Title (de)

PRODRUGS DES TYROSINKINASEINHIBITORS ZUR BEHANDLUNG VON KREBS

Title (fr)

PROMÉDICAMENTS DE L'INHIBITEUR DE TYROSINE KINASE POUR LE TRAITEMENT DU CANCER

Publication

EP 4021912 A1 20220706 (EN)

Application

EP 20857153 A 20200828

Priority

- CN 201910817505 A 20190830
- CN 201910818675 A 20190830
- CN 201910818779 A 20190830
- US 202062994364 P 20200325
- CA 2020051177 W 20200828

Abstract (en)

[origin: WO2021035360A1] There are provided compounds of Formula (I), and pharmaceutically acceptable salts and esters thereof, and pharmaceutical compositions thereof, useful for inhibition or modulation of the activity of tyrosine kinases and treatment of disease states or conditions mediated by tyrosine kinases, including cancers. (I)

IPC 8 full level

C07F 9/6558 (2006.01); **A61K 31/4439** (2006.01); **A61K 31/675** (2006.01); **A61P 35/00** (2006.01); **C07D 401/06** (2006.01); **C07D 401/14** (2006.01)

CPC (source: EP IL)

A61P 35/00 (2017.12 - EP IL); **C07D 401/06** (2013.01 - EP IL); **C07D 401/14** (2013.01 - EP IL); **C07D 405/12** (2013.01 - EP IL); **C07F 9/65583** (2013.01 - EP IL); **Y02P 20/55** (2015.11 - EP)

Designated contracting state (EPC)

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

Designated extension state (EPC)

BA ME

DOCDB simple family (publication)

WO 2021035360 A1 20210304; AU 2020338490 A1 20220317; CA 3147801 A1 20210304; EP 4021912 A1 20220706; EP 4021912 A4 20230823; IL 290798 A 20220401

DOCDB simple family (application)

CA 2020051177 W 20200828; AU 2020338490 A 20200828; CA 3147801 A 20200828; EP 20857153 A 20200828; IL 29079822 A 20220222